All In Biotech

Drug Trial Radar · NCT07038200

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jun 10, 2025

Primary completion

May 2028

Study completion Jul 2028

Sponsor

Lead sponsor
Avidity Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Jun 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

Conditions

  • Facioscapulohumeral Muscular Dystrophy
  • FSHD
  • FSHD - Facioscapulohumeral Muscular Dystrophy
  • FSHD1
  • FSHD2
  • Fascioscapulohumeral Muscular Dystrophy
  • Fascioscapulohumeral Muscular Dystrophy Type 1
  • Fascioscapulohumeral Muscular Dystrophy Type 2
  • Facioscapulohumeral Muscular Dystrophy 1
  • Facioscapulohumeral Dystrophy
  • Facio-Scapulo-Humeral Dystrophy
  • Facioscapulohumeral Muscular Dystrophy 2
  • Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1)
  • FSH Muscular Dystrophy
  • Landouzy Dejerine Dystrophy
  • Landouzy-Dejerine Muscular Dystrophy
  • Landouzy-Dejerine Syndrome

Interventions

  • AOC-1020Drug

    Del-brax will be administered by intravenous (IV) infusion.

  • PlaceboDrug

    Placebo will be administered by intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to Week 78 in Quantitative Muscle Testing (QMT) total composite score (PPN)Time frame: Baseline through Week 78

Locations

46 sites in 10 countries. Site status is shown where the registry gives one.

  • University of California Irvine

    Orange, California · Active not recruiting

  • Stanford University

    Palo Alto, California · Active not recruiting

  • University of Colorado

    Denver, Colorado · Active not recruiting

  • University of Florida

    Gainesville, Florida · Active not recruiting

  • University of Iowa

    Iowa City, Iowa · Active not recruiting

  • Kansas University Medical Center

    Kansas City, Kansas · Active not recruiting

  • Kennedy Krieger Institute

    Baltimore, Maryland · Active not recruiting

  • University of Massachusetts

    Worcester, Massachusetts · Active not recruiting

  • University of Rochester Medical Center

    Rochester, New York · Active not recruiting

  • Duke University

    Durham, North Carolina · Active not recruiting

  • Ohio State University

    Columbus, Ohio · Active not recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Active not recruiting

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas · Active not recruiting

  • Virginia Commonwealth University

    Richmond, Virginia · Active not recruiting

  • University of Calgary - Cumming School of Medicine

    Calgary, Alberta, Canada · Recruiting

  • University of Alberta Hospital

    Edmonton, Alberta, Canada · Recruiting

  • The Ottawa Hospital

    Ottawa, Ontario, Canada · Recruiting

  • Genge Partners Inc

    Montreal, Quebec, Canada · Recruiting

  • Aarhus University Hospital

    Aarhus, Denmark · Not yet recruiting

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Centre de Reference des Maladies Neuromusculaires et de la SLA - AP-HM Hopital de La Timone

    Marseille, France · Not yet recruiting

  • CHU de Montpellier - Hopital Gui de Chauliac

    Montpellier, France · Not yet recruiting

  • CHU de Nice - Hopital Pasteur 2 - Centre de reference des Maladies Neuromusculaires

    Nice, France · Not yet recruiting

  • AP-HP Hopital Pitie-Salpetriere

    Paris, France · Recruiting

  • Universitaetsklinikum Bonn

    Bonn, Germany · Recruiting

  • Georg-August-Universitaet Goettingen Stiftung oeffentlichen Rechts Universitaetsmedizin Goettingen

    Göttingen, Germany · Recruiting

  • Klinikum der Ludwig-Maximilians-Universitaet Muenchen

    München, Germany · Recruiting

  • Universitaetsklinikum Ulm

    Ulm, Germany · Recruiting

  • Fondazione Serena ETS - Centro Clinico NeMO Milano

    Milan, Italy · Recruiting

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, Italy · Recruiting

  • Azienda Ospedaliero-Universitaria Sant'Andrea

    Roma, Italy · Recruiting

  • Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

    Roma, Italy · Recruiting

  • National Hospital Organization Osaka Toneyama Medical Center

    Osaka, Japan · Recruiting

  • The University of Osaka Hospital

    Osaka, Japan · Recruiting

  • National Hospital Organization Sendai Nishitaga Hospital

    Sendai, Japan · Recruiting

  • National Center of Neurology and Psychiatry

    Tokyo, Japan · Recruiting

  • Academisch Ziekenhuis Leiden

    Leiden, Netherlands · Recruiting

  • Stichting Radboud Universitair Medisch Centrum

    Nijmegen, Netherlands · Recruiting

  • Hospital Universitari de Bellvitge

    Barcelona, Spain · Recruiting

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain · Recruiting

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.